MiMedx Group Inc (MDXG)

MiMedx Group Inc. is a healthcare company listed on the NASDAQ under the ticker MDXG. The company develops and distributes placental tissue allografts used in wound care, burn care, and surgical applications. Its products are made from human placental membrane, umbilical cord, and placental disc tissues processed through its proprietary PURION method, which is designed to preserve key biological components while using aseptic processing and terminal sterilization techniques.

MiMedx’s portfolio includes wound care products such as EPIFIX, EPICORD, EPIXPRESS, CHORIOFIX, EMERGE, CELERA, REGENKIT WOUND GEL, and EPIEFFECT sheets, as well as surgical and other offerings including AMNIOFIX, AMNIOBURN, AMNIOCORD, AXIOFILL, HELIOGEN, and AMNIOEFFECT. These products are used in areas such as lower extremity repair, plastic surgery, vascular surgery, and orthopedic repair and reconstruction. The company sells through a direct sales force and independent sales agents, and also works with individual customers and independent distributors in the United States. MiMedx was founded in 2006 and is headquartered in Marietta, Georgia.

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.